taxane-based chemotherapy

DRUG3 trials

Sponsors

Hoffmann-La Roche, Jenny C. Chang, MD

Conditions

Breast CancerMetastatic Breast Cancer

Phase 2

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

WithdrawnNCT02067416

Jenny C. Chang, MDBreast Cancer

Start: 2012-07-31End: 2014-06-30Updated: 2023-02-02

Phase 3

A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.

CompletedNCT00448591

Hoffmann-La RocheBreast Cancer

Start: 2006-09-30End: 2013-02-28Updated: 2015-05-25

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

RecruitingNCT05894239

Hoffmann-La RocheMetastatic Breast Cancer

Start: 2023-09-08End: 2032-12-28Target: 230Updated: 2026-05-01

Related Papers

Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).

2025-06-121 citations

INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with <i>PIK3CA</i>-mutated, HER2-positive advanced breast cancer (HER2+ aBC).

Journal of Clinical Oncology2024-06-014 citations

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

BMC Cancer2024-05-246 citations

Abstract PO2-19-09: INAVO122: a Phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients with PIK3CA-mutated, HER2-positive advanced breast cancer

Cancer Research2024-05-021 citations

A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors

The Oncologist2021-09-0918 citations

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial

The Breast2014-07-1847 citations

Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.

2011-12-2218 citations